Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 11/20 | 0.54 |
| ▸ | CCND1 | P24385 | 11/20 | 0.54 |
| ▸ | CDK6 | Q00534 | 11/20 | 0.54 |
| ▸ | CDK9 | P50750 | 11/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.54 |
| ▸ | CDK2 | P24941 | 4/20 | 0.54 |
| ▸ | CDK1 | P06493 | 3/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | CCND3 | P30281 | 2/20 | 0.39 |
| ▸ | CDK8 | P49336 | 3/20 | 0.39 |
| ▸ | CCNC | P24863 | 2/20 | 0.39 |
| ▸ | CDK7 | P50613 | 2/20 | 0.39 |
| ▸ | CCNH | P51946 | 2/20 | 0.39 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24304984 | 0.87 | CDK4 (0.55) | CDK4CCND1CDK6CDK9CCNT1 | |
| SCHEMBL21345115 | 0.86 | CDK6 (0.61) | CDK4CCND1CDK6CDK9CCNT1 | |
| SCHEMBL18081420 | 0.86 | CDK4 (0.54) | CDK4CCND1CDK6CDK9CCNT1 | |
| SCHEMBL17459809 | 0.86 | CDK6 (0.54) | CDK4CCND1CDK6CDK9CCNT1 | |
| SCHEMBL21345192 | 0.81 | CDK6 (0.61) | CDK4CCND1CDK6CDK9CCNT1 | |
| SCHEMBL28434216 | 0.75 | CDK6 (0.68) | CDK4CCND1CDK6CDK9CCNT1 | |
| SCHEMBL18081385 | 0.75 | CDK4 (0.44) | CDK4CCND1CDK6CDK9CCNT1 | |
| SCHEMBL18081363 | 0.72 | CDK6 (0.68) | CDK4CCND1CDK6CDK9CCNT1 | |
| SCHEMBL17459798 | 0.71 | HTT (0.42) | CDK4CCND1CDK6CDK9CCNT1 | |
| SCHEMBL21331753 | 0.71 | CDK4 (0.63) | CDK4CCND1CDK6CDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191469-B1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA INC (US) | 2021-12-15 | — | — | EP | disclosed |
| US-9878994-B2 | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof | BETA PHARMA INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170210726-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210726-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| WO-2016014904-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210726-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | CDK4, CDK3, CDK6 | CDK4 1/4885CCND1 35/4885CDK6 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.